Fused Imidazole Derivatives for HbF Induction in Sickle Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease, such as hydroxyurea, have limitations including side effects and do not adequately address the pathophysiology of sickle cell disease, which involves erythrocyte deformation, oxidative stress, and vaso-occlusion.
Innovation Solution
The use of substituted fused imidazole derivatives to upregulate HMOX1 expression and increase fetal hemoglobin (HbF) production, either alone or in combination with hydroxyurea or Nrf2 activators, to mitigate erythrocyte damage and vaso-occlusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxyurea is used to treat sickle cell disease, then fetal hemoglobin production is increased and clinical symptoms are improved, but side effects occur including DNA damage, reduced sperm counts, and iron nitrosyl Hb formation
Solution Approach 1:
The patent introduces heme as an intermediary substance that activates HO-1, which then produces CO and biliverdin. These intermediaries have protective effects without the toxic side effects of hydroxyurea. The CO produced acts as a signaling molecule that reduces inflammation and oxidative stress, while biliverdin has direct antioxidant properties, thereby achieving treatment effectiveness without harmful side effects.
Solution Approach 2:
The patent changes the biochemical parameters of treatment by administering heme or HO-1 activators instead of hydroxyurea. This shifts the therapeutic mechanism from direct hemoglobin modification to HO-1 pathway activation, resulting in different metabolic products (CO, biliverdin, bilirubin) that have beneficial effects without the cytotoxic side effects of hydroxyurea.
2Reliability
If current treatments are used, then some clinical symptoms are alleviated, but they do not adequately address the underlying pathophysiology involving oxidative stress and erythrocyte deformation
Solution Approach 1:
The patent employs HO-1 activation as a universal therapeutic mechanism that simultaneously addresses multiple pathophysiological aspects of sickle cell disease. By activating HO-1, the treatment concurrently reduces oxidative stress, decreases inflammation, prevents erythrocyte dehydration through band 3 clustering, and reduces vaso-occlusion, thereby providing comprehensive coverage of the disease's multifaceted pathophysiology with a single therapeutic approach.
3Object-affected harmful factors
If HO-1 is activated to counteract inflammation and oxidative stress, then erythrocyte damage is reduced, but the mechanism requires understanding complex biochemical pathways
Solution Approach 1:
The patent utilizes the body's own HO-1 enzyme system to combat oxidative stress and inflammation. By administering heme or HO-1 activators, the treatment harnesses the endogenous HO-1 pathway, which naturally produces protective substances (CO, biliverdin, bilirubin) that the body can process through existing metabolic routes. This self-service approach leverages the body's inherent biochemical machinery, avoiding the need for complex external intervention systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances HbF production, reducing sickling, increasing oxygen levels, and decreasing oxidative stress, thereby alleviating symptoms of sickle cell disease and related complications.
Implementation Method 1
HO-1 breaks down heme released during hemolysis thereby limiting oxidative stress and inflammation
Implementation Method 2
substituted fused imidazole derivatives that upregulate expression of HMOX1
Implementation Method 3
HU counteracts the pathophysiology of SCD by increasing the production of fetal hemoglobin (HbF)-containing erythrocytes
Implementation Method 4
The ensuing oxidative stress contributes to hemolysis, inactivation of nitric oxide (NO)
Implementation Method 5
The deoxygenated venous circulation causes a process of self-assembly (polymerization) that generates the sickled hemoglobin molecule (HbS)
Implementation Method 6
leukocytes are recruited to the activated endothelium of the venous circulation where it forms adhesive interactions with the activated endothelium
Implementation Method 7
Platelets and sickled erythrocytes have been demonstrated to aggregate via the formation of thrombospondin bridges
Data Source
AI summary
The present invention provides methods of treating sickle cell disease and related complications using compounds of Formula (I) and pharmaceutical compositions thereof either alone or in combination other active agents.